What It Targets Our AOD-9604 peptides are designed to target: Stubborn body fat and slow fat loss in clients already working on nutrition, steps, and strength training. Mild to moderate central adiposity where clients want incremental support rather than a primary weight-loss medication. Clients who cannot or do not wish to use GLP1s but still want to explore peptide-based metabolic support under a transparent riskbenefit discussion. Aesthetic-focused body recomposition journeys where even small improvements in fatmuscle balance can enhance contouring results
Anecdotal/observational reports (body composition, energy, recovery) exist in performance settings, but lack standardized dosing, controls, and validated endpoints
Symptoms of pernicious anemia include fatigue, weakness, and neurological changes
W hat you need: 1
Now the proportion, because three things are true at once
GLP-1 receptor agonists carry a boxed warning